Li Heming, Batth Izhar Singh, Qu Xiujuan, Xu Ling, Song Na, Wang Ruoyu, Liu Yunpeng
Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang City, 110001, China.
Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People's Republic of China.
Mol Cancer. 2017 Jan 30;16(1):6. doi: 10.1186/s12943-016-0576-5.
The insulin-like growth factor-I (IGF-I) signaling induces epithelial to mesenchymal transition (EMT) program and contributes to metastasis and drug resistance in several subtypes of tumors. In preclinical studies, targeting of the insulin-like growth factor-I receptor (IGF-IR) showed promising anti-tumor effects. Unfortunately, high expectations for anti-IGF-IR therapy encountered challenge and disappointment in numerous clinical trials. This review summarizes the regulation of EMT by IGF-I/IGF-IR signaling pathway and drug resistance mechanisms of targeting IGF-IR therapy. Most importantly, we address several factors in the regulation of IGF-I/IGF-IR-associated EMT progression that may be potential predictive biomarkers in targeted therapy.
胰岛素样生长因子-I（IGF-I）信号传导诱导上皮-间质转化（EMT）程序，并在多种肿瘤亚型中促进转移和耐药。在临床前研究中，靶向胰岛素样生长因子-I受体（IGF-IR）显示出有前景的抗肿瘤作用。不幸的是，对IGF-IR治疗的高度期望在众多临床试验中遭遇了挑战和失望。本综述总结了IGF-I/IGF-IR信号通路对EMT的调节以及靶向IGF-IR治疗的耐药机制。最重要的是，我们探讨了IGF-I/IGF-IR相关EMT进展调节中的几个因素，这些因素可能是靶向治疗中的潜在预测生物标志物。
